Financial

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Financial by Comments are Disabled

RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that Alexander M. Gold, M.D. has been appointed to the Company’s Board of Directors (the Board), effective June 13, 2024. “We are delighted to welcome Alex to our Board of Directors as we advance the late-stage clinical development of lorundrostat for the treatment of hypertension and related cardiorenal metabolic disorders,” stated Jon Congleton, Chief Executive Officer of Mineralys. “As a cardiologist and accomplished biopharmaceutical clinical development executive, Alex brings tremendous experience driving value for biopharmaceutical companies. We believe Alex’s track record of successful pipeline development, regulatory approvals, and joint ventures will make him be a valuable director and resource for the Company’s team.” “I am honored to join the Mineralys Board of Directors,” stated Dr. Gold. “I look forward to working with the Company’s executive team and fellow Board members to advance the treatment of cardiorenal metabolic disorders. There is significant potential with lorundrostat in offering a targeted treatment approach for hypertension and other diseases driven by dysregulated aldosterone.” Dr. Gold is a cardiologist with more than 20 years of experience leading the development, approval, and commercialization of new therapies. He has held executive positions at several biopharmaceutical companies that targeted numerous therapeutic areas, including cardiometabolic, renal, and inflammation. Currently, Dr. Gold is the Chief Medical Officer of a clinical-stage biotech company. Prior to his current role, he held the role of Head Medical Officer at Sanifit-CSL. He originally joined as Chief Medical Officer and President of Sanifit Inc. in 2017, which was then acquired by Vifor Pharma in January 2022 and subsequently by CSL Ltd. in August 2022. Prior to Sanifit, Dr. Gold held the role of Senior Vice President and Head of Clinical Development at Portola Pharmaceuticals. Prior to Portola Pharmaceuticals, Dr. Gold was Head of Clinical Development at Reata Pharmaceuticals. For 11 years he held multiple leadership positions at AstraZeneca, including the Executive Director and Development Leader for BRILINTA, CRESTOR and ONGLYZA. Dr. Gold is currently an Adjunct Professor at Stanford University School of Medicine. Dr. Gold completed his residency in internal medicine and fellowship in cardiology at the Beth Israel Deaconess Medical Center / Harvard Medical School in Boston and conducted translational and clinical research as a fellow in cardiovascular research at the Harvard Clinical Research Institute and was a Scholar in Clinical Science. Dr. Gold received his M.D. from Harvard Medical School and his B.A in Biology from Brandeis University. In addition, the Company announced the resignation of Olivier Litzka, Ph.D. from its Board, effective June 13, 2024. Dr. Litzka stated: “It was an honor for me to serve on the Mineralys Board since the Company’s final private financing round prior to the initial public offering. The Company has shown tremendous progress, which is due to its exceptionally talented and hard working team. As a venture capital investor, I’ve decided to step down in order to make room for new, well-suited board members like Alex Gold to support the Company going forward. I wish Mineralys all the best on its path forward.” “The Board and I would like to express our collective gratitude to Olivier for his contributions and dedication to the Board. We wish him future success as he turns his attention to other venture investments at Andera Partners,” stated Mr. Congleton. About LorundrostatLorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects. In a Phase 2, proof-of-concept trial (Target-HTN) in uncontrolled or resistant hypertensive subjects, once-daily lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension, in both automated office blood pressure measurement and 24-hour ambulatory blood pressure monitoring. Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia. About Mineralys TherapeuticsMineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter. Forward Looking Statements Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Investor Relationsinvestorrelations@mineralystx.com Media RelationsTom WeibleElixir Health Public RelationsPhone: (1) 515-707-9678Email: tweible@elixirhealthpr.com

Continue Reading →

CARMAT Announces the Start of the Equitization of the First Tranche of Its EIB Loan

Financial by 0 comments

June 13, 2024 12:00 PM Eastern Daylight Time PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR): On February 14, 2023, the French financial markets authority (Autorité des marchés financiers) invited companies issuing equity securities or securities giving access to capital on a staggered basis to adopt a standard communication and warning on the […]

Continue Reading →

Simpson Interventions Announces Appointment of Dr. Joseph Knight as CEO

Financial by 0 comments

June 12, 2024 10:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced the appointment of Dr. Joseph Knight to the role of Chief Executive Officer, effective May 1st, 2024. He replaces Simpson Interventions’ Founder and previous CEO, […]

Continue Reading →

Positron Corporation Enters Agreement to Acquire FDA 510(k) for NeuSight PET-CT

Financial by Comments are Disabled

Niagara Falls, NY, June 12, 2024 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical support services, is pleased to announce it has entered an agreement to acquire the FDA 510(k) for the NeuSight PET-CT from its cooperative partner Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.   A 510(k) is a premarket submission made to the FDA (U.S. Food and Drug Administration) to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device. Positron’s ownership of the existing 510(k) and FDA clearance will enable the marketing and sale of the NeuSight PET-CT 64 slice imaging system. This 510(k) also will facilitate future FDA clearances, including for the Company’s Affinity PET-CT 4D 64 slice system. This agreement allows Positron to immediately market and sell the NeuSight PET-CT, with plans to introduce Positron’s Affinity PET-CT 4D pending acceptance of an amended 510(k) submission.   Adel Abdullah, President of Positron stated, “Gaining the 510(k) is a significant milestone in Positron’s mission to offer outstanding PET-CT technology and solutions to healthcare practices and hospitals serving both the cardiac and oncology segments of molecular imaging. Our PET imaging product line will now feature PET-CT which will expand access for physicians and practitioners seeking to utilize the full capabilities of the PET modality in nuclear cardiology and oncology.  PET-CT imaging remains at the forefront of oncology studies and has become vital to the future of nuclear cardiology. With the addition of PET-CT, Positron has a range of core products that blend cutting edge technology with strong economics, appealing to most nuclear imaging specialist and practices.” Mr. Abdullah further added, “We appreciate the full support of Neusoft Medical Systems whose unwavering support and expertise in imaging technologies and extensive R&D continues to enhance our current and future capabilities. I am confident in Positron’s important role in advancing the PET modality and our commitment to delivering the best value in the industry.” About Positron Corporation Positron Corporation is a medical technology company that co-develops, manufactures, and sells  state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine. Positron’s Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.  Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.    About Neusoft Medical Systems Co., Ltd. Neusoft Medical Systems is a leading global clinical diagnosis and treatment solution provider, headquartered in China. Neusoft Medical Systems is constantly innovating its portfolio of medical imaging diagnosis and clinical solutions in CT, MRI, DSA, XR, PET/CT, RT, US and IVD. Neusoft Medical Systems also is developing MDaaS (Medical Devices & Data as a Service), a strategic product line built using the Internet, big data, artificial intelligence, combined with other technologies improving medical institutions’ ability to diagnose and treat patients, achieving operational excellence. Innovation is always the driving force of Neusoft Medical Systems. Neusoft Medical Systems is collaborating with global scientists and medical institutions dedicated to advancing the technology of medical imaging solutions. Together with 45,000 installations in more than 110 countries, Neusoft Medical Systems provides advanced, high-quality medical imaging solutions to patients around the world. Neusoft Medical Systems is dedicated to being an excellent value innovator of global healthcare services. Through innovation and excellent operations, Neusoft Medical Systems is advancing healthcare products across a wide range of medical solutions and services to enhance global healthcare for all. Forward-Looking Statements  This press release contains statements which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future. FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com

Continue Reading →

University Hospitals Transforms Patient Care with Aidoc’s AI-Enabled Solutions Across Its Entire Health System

Financial by Comments are Disabled

Aidoc aiOS™ integration across 13 hospitals focuses on enhancing clinical outcomes and streamlining workflow with access to 17 FDA-cleared AI algorithmsCLEVELAND, June 12, 2024 /PRNewswire/ — University Hospitals (UH) has announced a major advancement in its AI strategy with the deployment of Aidoc’s comprehensive AI platform (aiOS™) across 13 of its hospitals and dozens of its outpatient locations. This initiative marks a significant leap forward in leveraging cutting-edge technology for superior patient outcomes.

Continue Reading

Image of University Hospitals Medical Center Campus in Cleveland, Oh. (PRNewsfoto/Aidoc)

University Hospitals Logo (PRNewsfoto/Aidoc)

Driven by a commitment to provide the highest standard of care, UH sought a standardized, hyper-accurate AI platform that could be seamlessly integrated across its network of academic hospitals and outpatient locations. Having utilized AI in various small-scale applications, UH chose to expand its capabilities with Aidoc to empower care teams with the information they need to address some of today’s most pressing medical issues.

Patients at UH will benefit from faster diagnosis and treatment of acute conditions such as pulmonary embolism, aortic dissection, vertebral compression fracture and pneumothorax. When a patient arrives at a UH facility and undergoes a CT scan for an injury or pain, Aidoc’s AI analyzes the scan using its comprehensive algorithms. The technology identifies both expected and unexpected findings, helps physicians prioritize urgent cases and ensures all flagged conditions are reviewed by the care team. Aidoc’s AI facilitates communication between the care team to enhance collaboration and speed up treatment.
Key Benefits of Aidoc for University Hospitals
Seamless integration across the entire health network
Immediate access to critical patient information
Expedited care and improved patient outcomes
Access to all 17 FDA-cleared AI algorithms for triage, quantification and care coordination
“Today’s care delivery is incredibly complex with numerous moving parts,” shared Dr. Donna Plecha, Chair of Radiology at University Hospitals.” Aidoc’s AI technology assists our radiologists in evaluating various patient images, allowing our clinicians to access precise, actionable data quickly. The AI technology enables our care teams to be more accurate and efficient leading to even more exceptional care for our patients.”The agreement leverages Aidoc’s proprietary aiOS™, a groundbreaking platform that addresses common AI implementation challenges such as integrating with existing IT systems, ensuring EHR compatibility, and managing data and reporting. This comprehensive approach ensures that UH can provide leading-edge care while maintaining operational efficiency and clinical excellence.”We are thrilled to collaborate with University Hospitals to drive healthcare innovation through our AI solutions,” said Elad Walach, CEO, Aidoc. “University Hospitals’ visionary approach to healthcare and dedication to integrating technology sets a new standard for patient care. UH is not only enhancing care coordination and streamlining workflows but also ensuring every patient receives the precise, timely and exceptional care they deserve. UH’s commitment to medical ingenuity and excellence is truly transformative.”By integrating Aidoc’s AI platform, University Hospitals ensures seamless deployment and minimal technical challenges, allowing for a collaborative approach to continuous monitoring and governance. This partnership not only enhances patient safety and care but also enables UH to maintain high standards in AI performance and reliability. Through this collaborative effort, UH can focus more on patient care, ensuring every patient receives the best possible treatment with the aid of AI technology.About University Hospitals Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system’s flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, the Technion Israel Institute of Technology and National Taiwan University College of Medicine. The main campus also includes the UH Rainbow Babies & Children’s Hospital, ranked among the top children’s hospitals in the nation; UH MacDonald Women’s Hospital, Ohio’s only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visit UHhospitals.org.About AidocAidoc is a pioneering force in clinical AI. We focus on aiding and empowering healthcare teams to optimize patient treatment, which results in improved economic value and clinical outcomes. Our clinically proven AI solutions eliminate silos, increase efficiencies, and improve outcomes by delivering critical information when and where care teams need it leading to immediate collective action. Built on Aidoc’s proprietary aiOS™, we analyze and aggregate medical data to enable care teams to operationalize the unexpected and work seamlessly with a continued focus on the patient. Used in more than 1,000 medical centers worldwide, Aidoc has the most FDA clearances (17) in clinical AI and its AI-based solutions cover 75 percent of patient populations, enabling physicians to make informed decisions based on real-time data. Aidoc AI is always on, running in the background to change the foreground. Visit Aidoc.com to see how we are connecting all points of care with always on AI.Photo – https://mma.prnewswire.com/media/2436134/Aidoc_UH.jpgLogo – https://mma.prnewswire.com/media/2015772/4756850/Aidoc_Always_On_AI_Logo.jpgLogo – https://mma.prnewswire.com/media/2436135/University_Hospitals_Logo.jpgSOURCE Aidoc

Continue Reading →

Kardium Announces $104M in New Financing for Innovative Atrial Fibrillation Treatment

Financial by 0 comments

VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $104 million in a new financing round. The round is led by existing investor Fidelity Management & Research Company, together with follow-on participation by funds and accounts advised by T. Rowe […]

Continue Reading →

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

Financial Peripheral/Endo by 0 comments

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage […]

Continue Reading →

Biome Analytics Welcomes Brian Maher, MPH, as Vice President of Business Development

Financial by 0 comments

SAN FRANCISCO–(BUSINESS WIRE)–Biome Analytics, the leading cardiovascular performance management company, announced today that Brian Maher, MPH, has been appointed as the new Vice President of Business Development. “We are delighted to welcome Brian to the Biome team. His deep understanding of the healthcare landscape and thought leadership will undoubtedly propel […]

Continue Reading →

Medtronic chairman and CEO Geoff Martha to speak at Goldman Sachs global healthcare conference

Financial by Comments are Disabled

DUBLIN, June 6, 2024  /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 45th annual Goldman Sachs global healthcare conference on Tuesday, June 11, 2024.
Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the company beginning at 10:40 a.m. EDT (9:40 a.m. CDT).
A live webcast of the Q&A session will be available on June 11, 2024, by clicking on the Events link at http://investorrelations.medtronic.com. An archive of the Q&A session will be available on the same webpage later in the day.
About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn. 
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 
Contacts:
Erika Winkels                        Ryan WeispfenningPublic Relations                   Investor Relations+1-763-526-8478                 +1-763-505-4626
SOURCE Medtronic plc

Continue Reading →

RapidAI Wins 2024 MedTech Breakthrough Award For “Best Care Coordination Platform”

Financial by Comments are Disabled

LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) — MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market, today announced that RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, has been selected as the winner of the “Best Care Coordination Platform” award in the 8th annual MedTech Breakthrough Awards program. The 2024 MedTech Breakthrough Award recognizes the breakthrough innovation of the RapidAI Clinical Platform, a proven solution that provides clinicians from thousands of hospitals in over 100 countries with deep clinical context to make faster and more informed treatment decisions while also enhancing their confidence in diagnosis. By opening up the care pathway through the power of AI and enhanced connectivity, RapidAI transforms the quality of care delivered to patients by facilitating faster, more informed decision-making. “RapidAI’s Clinical Platform moves the needle by pairing together the most clinically validated deep AI algorithms with workflow efficiencies that take the friction out of the healthcare system, making it our ‘Best Care Coordination Platform’ for 2024,” said Steve Johansson, managing director of MedTech Breakthrough. “The workflow efficiencies and connectivity that RapidAI enables ensures that every patient, no matter where they go for care, has access to the most trusted technology and clinical specialists – all while delivering measurable financial and operational impact.” According to the World Stroke Organization (WSO), over 100 million people in the world have experienced a stroke, of which over half will die as a result. On top of this, the WSO estimates 143 million healthy years of life are lost for those who do survive. For stroke patients alone, RapidAI’s technology has been shown to reduce both length-of-stay and non-fatal complications, increase mechanical thrombectomy procedure volume, reduce the number of costly futile transfers, and give radiologists and hospital staff valuable time back through its cutting-edge AI and workflow solution. “We are honored that the RapidAI Clinical Platform has been recognized by MedTech Breakthrough for the care orchestration and workflow efficiencies that it enables,” said Karim Karti, CEO of RapidAI. “By enhancing cross-department collaboration and team communication, the RapidAI Clinical Platform benefits care teams by fostering prompt collaboration and mitigating wasted time and resources. Our commitment to delivering clinical, financial, and operational excellence in advanced artificial intelligence distinguishes our platform from other healthcare AI imaging solutions in neurology, cardiology, and beyond. ” The mission of the MedTech Breakthrough Awards is to honor excellence and recognize innovation, hard work, and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and many more. This year’s program attracted thousands of nominations from over 18 different countries throughout the world. About MedTech BreakthroughPart of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.  Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose. About RapidAIRapidAI is the global leader in AI imaging analysis and clinical decision support, leading the next evolution in patient workflow technology and clinical decision-making. The company has helped set a new standard for stroke care with its presence in over 2,200 hospitals across more than 100 countries. Its clinically deep AI technology has played a pivotal role in over 25 clinical trials worldwide, 350 publications, and 11 NEJM articles, and was instrumental in changing the guidelines for stroke care. Today, the company continues to transform the clinical landscape by enhancing operational efficiency for improved patient outcomes in stroke care and beyond. This includes empowering healthcare professionals to make confident decisions, driving better operational performance, and providing tangible financial ROI – all while ensuring that every patient, regardless of their entry point into the healthcare system, has access to world-class technology and clinical expertise.

Continue Reading →
1 … 78 79 80 81 82 … 485